ADC THERAPEUTICS SA (ADCT) Stock Analyst Ratings
USA - NYSE:ADCT - CH0499880968 - Common Stock
4.43 USD
+0.14 (+3.26%)
4.39 USD
-0.04 (-0.9%)
ChartMill assigns a Buy % Consensus number of 87% to ADCT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.42. This target is 89.95% above the current price.
ADCT was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about ADCT.
In the previous month the buy percentage consensus was at a similar level.
ADCT was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-03-31 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-24 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-01-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-05-30 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-05 | Guggenheim | Reiterate | Buy |
| 2024-03-28 | Guggenheim | Initiate | Buy |
| 2024-03-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-09 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-10 | JP Morgan | Upgrade | Underweight -> Neutral |
ADC THERAPEUTICS SA / ADCT FAQ
What do analysts expect the price target to be for ADC THERAPEUTICS SA (ADCT)?
12 analysts have analysed ADCT and the average price target is 8.41 USD. This implies a price increase of 89.95% is expected in the next year compared to the current price of 4.43.
What is the consensus rating for ADCT stock?
The consensus rating for ADC THERAPEUTICS SA (ADCT) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed ADC THERAPEUTICS SA (ADCT)?
The number of analysts covering ADC THERAPEUTICS SA (ADCT) is 12.